Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?

International Journal of Developmental Biology

Volumn 55, Issue 4-5, 2011, Pages 563-567

  Hlushchuk, Ruslan ^a   Makanya, Andrew N ^a,b   Djonov, Valentin ^a,c  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antiangiogenic therapy; Anticancer therapy; Escape mechanism; Intussusce ptive angiogenesis; Protein tyrosine kinase inhibitor; Tumor recovery

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CEDIRANIB; VASCULOTROPIN; VATALANIB;

ADAPTATION; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; DRUG RESPONSE; DRUG TARGETING; INSULINOMA; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR ESCAPE; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79961017047     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.103231rh     Document Type: Article

References (39)

1. ALESSI P, LEALI D, CAMOZZI M, CANTELMO A, ALBINI A, PRESTA M (2009). Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 20: 225-234.
2. AUSPRUNK DH, KNIGHTON DR, FOLKMAN J (1974). Differentiation of vascular endothelium in the chick chorioallantois: a structural and autoradiographic study. Dev Biol 38: 237-248.
3. BATCHELOR TT, SORENSEN AG, DI TE, ZHANG WT, DUDA DG, COHEN KS, KOZAK KR, CAHILL DP, CHEN PJ, ZHU M, ANCUKIEWICZ M, MRUGALA MM, PLOTKIN S, DRAPPATZ J, LOUIS DN, IVY P, SCADDEN DT, BENNER T, LOEFFLER JS, WEN PY, JAIN RK (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11: 83-95.
4. BATES DO, HILLMAN NJ, WILLIAMS B, NEAL CR, POCOCK TM (2002). Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 200: 581-597.
5. BERGERS G, HANAHAN D (2008). Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
6. BROXTERMAN HJ, LANKELMA J, HOEKMAN K (2003). Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Updat 6: 111-127.
7. BURRI PH, DJONOV V (2002). Intussusceptive angiogenesis--the alternative to capillary sprouting. Mol Aspects Med 23: S1-27.
8. BURRI PH, HLUSHCHUK R, DJONOV V (2004). Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn 231: 474-488.
9. CARMELIET P, DE SF, LOGES S, MAZZONE M (2009). Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 6: 315-326.
10. CASANOVAS O, HICKLIN DJ, BERGERS G, HANAHAN D (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
11. DJONOV V, BAUM O, BURRI PH (2003). Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 314: 107-117.
12. DOME B, HENDRIX MJ, PAKU S, TOVARI J, TIMAR J (2007). Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170: 1-15.
13. DREVS J, MULLER-DRIVER R, WITTIG C, FUXIUS S, ESSER N, HUGENSCHMIDT H, KONERDING MA, ALLEGRINI PR, WOOD J, HENNIG J, UNGER C, MARME D (2002). PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022.
14. ELLIS LM, HICKLIN DJ (2008). Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14: 6371-6375.
15. FOLKMAN J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
16. GERBER HP, DIXIT V, FERRARA N (1998). Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316.
17. GREENBERG JI, SHIELDS DJ, BARILLAS SG, ACEVEDO LM, MURPHY E, HUANG J, SCHEPPKE L, STOCKMANN C, JOHNSON RS, ANGLE N, CHERESH DA (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456: 809-813.
18. HANAHAN D, FOLKMAN J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
19. HELFRICH I, SCHEFFRAHN I, BARTLING S, WEIS J, VON F, V, MIDDLETON M, KATO M, ERGUN S, SCHADENDORF D (2010). Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207: 491-503.
20. HILLEN F, GRIFFIOEN AW (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26: 489-502.
21. HLUSHCHUK R, BAUM O, GRUBER G, WOOD J, DJONOV V (2007). The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation. Microcirculation 14: 813-825.
22. HLUSHCHUK R, RIESTERER O, BAUM O, WOOD J, GRUBER G, PRUSCHY M, DJONOV V (2008). Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 173: 1173-1185.
23. JAIN RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
24. JAIN RK (2008). Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8: 309-316.
25. JAIN RK, DUDA DG, CLARK JW, LOEFFLER JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40.
26. KRAMER I, LIPP HP (2007). Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 32: 1-14.
27. KU DD, ZALESKI JK, LIU S, BROCK TA (1993). Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265: H586-H592.
28. MA J, WAXMAN DJ (2008). Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670-3684.
29. MAKANYA AN, HLUSHCHUK R, DJONOV VG (2009). Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis 12: 113-123.
30. MILLER KD, SWEENEY CJ, SLEDGE GW, JR. (2003). The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol 14: 20-28.
31. MILLER KD, SWEENEY CJ, SLEDGE GW, JR. (2005). Can tumor angiogenesis be inhibited without resistance?. In Mechanisms of Angiogenesis (Eds. M. Clauss, G. Breier). EXS. Birkhäuser, Basel, pp. 95-112.
32. NAKAMURA K, TAGUCHI E, MIURA T, YAMAMOTO A, TAKAHASHI K, BICHAT F, GUILBAUD N, HASEGAWA K, KUBO K, FUJIWARA Y, SUZUKI R, KUBO K, SHIBUYA M, ISAE T (2006). KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res 66: 9134-9142.
33. NAKAMURA K, YAMAMOTO A, KAMISHOHARA M, TAKAHASHI K, TAGUCHI E, MIURA T, KUBO K, SHIBUYA M, ISOE T (2004). KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 3: 1639-1649.
34. RUDIN M, MCSHEEHY PM, ALLEGRINI PR, RAUSCH M, BAUMANN D, BECQUET M, BRECHT K, BRUEGGEN J, FERRETTI S, SCHAEFFER F, SCHNELL C, WOOD J (2005). PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed 18: 308-321.
35. RUGGERI B, SINGH J, GINGRICH D, ANGELES T, ALBOM M, YANG S, CHANG H, ROBINSON C, HUNTER K, DOBRZANSKI P, JONES-BOLIN S, PRITCHARD S, AIMONE L, KLEIN-SZANTO A, HERBERT JM, BONO F, SCHAEFFER P, CASELLAS P, BOURIE B, PILI R, ISAACS J, ATOR M, HUDKINS R, VAUGHT J, MALLAMO J, DIONNE C (2003). CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63: 5978-5991.
36. SENNINO B, KUHNERT F, TABRUYN SP, MANCUSO MR, HU-LOWE DD, KUO CJ, MCDONALD DM (2009). Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 69: 4527-4536.
37. SOLTAU J, DREVS J (2009). Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev Anticancer Ther 9: 649-662.
38. VAN HINSBERGH VW, KOOLWIJK P (2008). Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78: 203-212.
39. YOSHIJI H, HARRIS SR, THORGEIRSSON UP (1997). Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57: 3924-3928.